Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.

Scientific reports - 27 Jun 2016

Sandhöfer Nadine, Bauer Julia, Reiter Katrin, Dufour Annika, Rothenberg Maja, Konstandin Nikola P, Zellmeier Evelyn, Tizazu Belay, Greif Philipp A, Metzeler Klaus H, Hiddemann Wolfgang, Polzer Harald, Spiekermann Karsten

Abstract excerpt

In acute myeloid leukemia (AML), the Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes. Recently, a new and recurrent juxtamembrane deletion mutation (p.Q569Vfs*2) resulting in a truncated receptor was identified. The mutated receptor is expressed on the cell surface and still binds its ligand but loses the ability to activate ERK signaling. FLT3 p.Q569fs-expressing Ba/F3 cells show no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FLT3 gene

Share to Genes, Dominant

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 27346558
DOI: 10.1038/srep28032
PMCID: PMC4921855

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.PMID 27346558Read ↗

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AMLSemantic proximity Read ↗

Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.Semantic proximity Read ↗

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.Semantic proximity Read ↗

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.Semantic proximity Read ↗

Identification of a novel mutation of the FLT3 gene located on the juxtamembrane domain from acute myeloid leukemia patients.Semantic proximity Read ↗

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.Semantic proximity Read ↗

Normal and oncogenic FLT3.Semantic proximity Read ↗

Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.Semantic proximity Read ↗

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.Semantic proximity Read ↗

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.Semantic proximity Read ↗

Mutant FLT3 signaling contributes to a block in myeloid differentiationSemantic proximity Read ↗

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.